Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Domácí trénink dýchacích svalů a aerobní cvičení pro zlepšení plicního zdraví u současných a bývalých kuřáků

5. listopadu 2026 aktualizováno: Roswell Park Cancer Institute

Účinky tréninku dýchacích svalů a aerobního cvičení na zdraví plic u kuřáků: Pilotní paralelní skupinová studie pro prevenci rakoviny plic

This clinical trial studies whether home-based respiratory muscle training (RMT) and aerobic exercise (AE) programs can be used to improve lung health in current and former cigarette smokers. Lung cancer, the leading cause of cancer death, is overwhelmingly caused by exposure to cigarette smoke. Research suggests that daily activity reduces lung cancer risk in current and former smokers. However, current and former smokers are generally not active and new approaches to improve lung health are needed. During the home-based RMT program, participants use a handheld device to complete breathing exercise sessions consisting of breathing in and out against adjustable resistance. During the home-based AE program, participants complete aerobic exercises using a stationary bike working at a moderate workload against adjustable resistance. The home-based RMT and AE programs may be effective ways to strengthen the breathing muscles, which may improve lung health in current and former cigarette smokers.

Přehled studie

Detailní popis

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of delivering a home-based AE and RMT program in individuals at high risk for lung cancer.

II. Assess the effects of AE and RMT on patient-reported outcomes (PROs), including QoL, fatigue, dyspnea, performance metrics such as respiratory muscle strength and lower extremity strength; the 6-minute walk test; and daily activity levels in high-risk individuals.

III. Investigate whether RMT and/or AE improve peripheral and exhaled biomarkers associated with lung injury, inflammation, and/or oxidative stress.

OUTLINE: Participants scheduled for a computed tomography (CT) scan are assigned to cohort A, participants who call the New York State Quitline (NYSQL) are assigned to cohort B.

COHORT A: Participants are randomized to 1 of 3 arms.

ARM I: Participants complete RMT sessions via the Power Lung device over 20-30 minutes each consisting of three sets of 15 breaths at a gradual increase in resistance, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call once a week (QW) to provide support, enhance safety, and promote training compliance on study.

ARM II: Participants complete tailored intensity AE cycling sessions progressing to over 30 minutes each, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study.

ARM III: Participants receive education on AE and RMT including recommendations aligned with current guidelines 5 days a week for 12 weeks.

COHORT B: Participants are randomized to 1 of 2 arms.

ARM IV: Participants complete RMT sessions as in arm I for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study.

ARM V: Participants receive education on AE and RMT as in arm III on study.

Additionally, all patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

After completion of study intervention, participants may be optionally followed up at week 24.

Typ studie

Intervenční

Zápis (Odhadovaný)

200

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • New York
      • Buffalo, New York, Spojené státy, 14263
        • Roswell Park Cancer Institute
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Andrew D. Ray

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

50 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Age ≥ 50 years old
  • Current smoker with a ≥ 20-pack-years history
  • Former smoker within the past 15 years, with a history of ≥ 20 pack-years (CT scan cohort only)
  • Participant must be able to speak, read and comprehend English language
  • Cognitively capable of following direction and performing the intervention
  • Understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Any previous lung cancer diagnoses and or undergoing treatment for any cancer
  • Recent pneumonia, bronchitis, or other inflammatory conditions in the lungs, including but limited to chronic obstructive pulmonary disease (COPD) and/or asthma exacerbation within the previous 6 months
  • Have uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Cohort A Arm I (RMT)

Participants complete RMT sessions via the Power Lung device over 20-30 minutes each consisting of three sets of 15 breaths at a gradual increase in resistance, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ancillary studies

Ostatní jména:
  • Testování fyzické zdatnosti
  • Testování fyzikálních funkcí

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Complete RMT sessions

Ostatní jména:
  • RMT

Receive virtually supervised session/call

Ostatní jména:
  • Podpůrná terapie
  • Řízení symptomů
  • Terapie, podpůrná
Experimentální: Cohort A Arm II (AE)

Participants complete tailored intensity AE cycling sessions progressing to over 30 minutes each, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ancillary studies

Ostatní jména:
  • Testování fyzické zdatnosti
  • Testování fyzikálních funkcí

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Receive virtually supervised session/call

Ostatní jména:
  • Podpůrná terapie
  • Řízení symptomů
  • Terapie, podpůrná

Complete tailored intensity AE cycling sessions

Ostatní jména:
  • Aerobní aktivita
Aktivní komparátor: Cohort A Arm III (AE and RMT education)

Participants receive education on AE and RMT including recommendations aligned with current guidelines 5 days a week for 12 weeks. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ancillary studies

Ostatní jména:
  • Testování fyzické zdatnosti
  • Testování fyzikálních funkcí

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Receive AE and RMT education

Ostatní jména:
  • Výchova k intervenci
  • Intervence vzděláváním
  • Intervence prostřednictvím vzdělávání
  • Intervence, Vzdělávací
Experimentální: Cohort B Arm IV (RMT)

Participants complete RMT sessions as in arm I for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ostatní jména:
  • Testování fyzické zdatnosti
  • Testování fyzikálních funkcí

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Complete RMT sessions

Ostatní jména:
  • RMT

Receive virtually supervised session/call

Ostatní jména:
  • Podpůrná terapie
  • Řízení symptomů
  • Terapie, podpůrná
Aktivní komparátor: Cohort B Arm V (AE and RMT education)

Participants receive education on AE and RMT as in arm III on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ostatní jména:
  • Testování fyzické zdatnosti
  • Testování fyzikálních funkcí

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Receive AE and RMT education

Ostatní jména:
  • Výchova k intervenci
  • Intervence vzděláváním
  • Intervence prostřednictvím vzdělávání
  • Intervence, Vzdělávací

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Compliance rate (Feasibility)
Časové okno: Up to 12 weeks

The primary objective is in the feasibility of conducting the respiratory muscle training (RMT) and aerobic exercise (AE) intervention relative to the sham control. In the RMT group, overall compliance (e.g., compliant at all time points) will be estimated using 90% confidence intervals (CIs) obtained Clopper-Pearson method. The lower bounds will define a plausible lower limit for true (unobserved) compliance rates. Additionally, compliance status will be modeled as a function of time (e.g., week), and pre-specified exogenous factors using a generalized estimating equation logistic regression model (autoregressive covariance structure). Estimates of compliance rates will be obtained by time-point and tests about the appropriate contrasts of model estimates will be used to determine if there is a time trend.

Up to 12 weeks
Adherence rate (Feasibility)
Časové okno: Up to 12 weeks

The primary objective is in the feasibility of conducting the RMT and AE intervention relative to the sham control. In the RMT group, overall adherence (complete ≥ 70% of sessions) rates will be estimated using 90% CIs obtained Clopper-Pearson method. The lower bounds will define a plausible lower limit for true (unobserved) adherence rates.

Up to 12 weeks
Assessing inspiratory and expiratory muscle strength
Časové okno: At baseline, 6 weeks, and 12 weeks

Participants will complete 3 sets of 15 breaths, 5 days/week using commercially available Power Lung. resistance will be increased 5-10% every week . Participants will rate and log their effort

At baseline, 6 weeks, and 12 weeks
change in St. George Respiratory Questionnaire (SGRQ)
Časové okno: At baseline, 6 weeks, and 12 weeks

The SGRQ comprises of 50 items and consists of two parts. Scores range from 0-100, with higher scores indicating worse quality of life.

At baseline, 6 weeks, and 12 weeks
Functional capacity
Časové okno: At baseline, 6 weeks, and 12 weeks

Measured by the 6-Minute Walk Test. Will be summarized at pre-, 6-week and post-intervention timepoints, regardless of treatment regimen, using the appropriate descriptive statistics and graphically summarized. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. Comparisons at the 6-week and 3-month follow-up visits will be secondary and will only be performed if the primary comparison for the corresponding endpoint reaches statistical significance. For cohort A, Bonferroni's correction will be applied to adjust for three pairwise comparisons.

At baseline, 6 weeks, and 12 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Lower extremity strength
Časové okno: At baseline and 12 weeks

Measured using the 30-Second Sit-to-Stand Test. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

At baseline and 12 weeks
Physical performance
Časové okno: At baseline and 12 weeks

Measured using the Short Physical Performance Battery. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

At baseline and 12 weeks
Physical activity levels
Časové okno: Up to 12 weeks

daily step counts and minutes at various intensity levels will be monitored with an activity tracker. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

Up to 12 weeks
Patient-reported outcomes on Fatigue
Časové okno: At baseline and 12 weeks

he Functional Assessment of Chronic Illness Therapy (FACIT- fatigue scale) is a 13-item patient-reported measure of fatigue. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52. The higher the score, the lower the score the greater the fatigue severity

At baseline and 12 weeks
High-sensitivity C-reactive protein
Časové okno: At baseline and 12 weeks

The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

At baseline and 12 weeks
Cardiac biomarkers
Časové okno: At baseline and at 12 weeks

Will assess cardiac biomarkers, such as high-sensitivity troponin T and N-terminal pro-brain natriuretic peptide. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. Biomarker data will be appropriately transformed prior to analysis to meet model assumptions.

At baseline and at 12 weeks
Dyspnea patient reported response
Časové okno: Baseline and at 12 weeks

he Dyspnea-12 describes the different qualitative dimensions of breathlessness. Each 12- item (seven for the physical and five for the affective components) score ranges from 'none' (score 0) to 'severe' (score 3) with a total score ranging from 0 to 36 (lower is better), a physical score ranging from 0 to 21 and an affective score ranging from 0 to 15

Baseline and at 12 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Andrew D Ray, Roswell Park Cancer Institute

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

15. prosince 2026

Primární dokončení (Odhadovaný)

1. května 2029

Dokončení studie (Odhadovaný)

1. května 2029

Termíny zápisu do studia

První předloženo

1. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

20. dubna 2026

První zveřejněno (Aktuální)

28. dubna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

6. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

5. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit